Rebolledo-García D, González-Vargas Z, Medina-López PO, Salgado CI

Idioma: Español
Referencias bibliográficas: 36
Paginas: 80-93
Archivo PDF: 546.14 Kb.

RESUMEN

En la actualidad el síndrome de Guillain Barré (SGB) es la causa más frecuente de parálisis flácida aguda. La forma clásica de síndrome no ha sufrido modificaciones importantes en su comportamiento clínico, sin embargo, el espectro de variantes clínicas del síndrome es extenso, sustentado en los avances de la biología molecular y la inmunología que han permitido caracterizar mejor estas formas del SGB. Los anticuerpos anti-gangliósidos han reestructurado los criterios, ya que aumentan la sensibilidad como la especificidad del diagnóstico; debido a ello, los criterios clásicos son insuficientes para lograr una adecuada clasificación y discriminar los imitadores del síndrome. La evolución de los criterios debe cambiar la perspectiva en el abordaje del cuadro y normar la conducta terapéutica, sin sobrepasar el juicio clínico de la práctica médica diaria.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Clifford R. History of British Neurology. 1era edición: Imperial College Press; 2012.

2. Guillain Barré & Associated Inflammatory Neuropathies, 2010. (Accesed 28 diciembre, 2015 at http://www.gaincharity.org.uk/history-of-gbs/info_71.html)

3. Van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008; 7: 939–50.

4. García Ramos GS, Cacho Díaz B. Síndrome de Guillain-Barré (SGB). Diagnóstico diferencial. Rev Mex Neuroci. 2005; 6(5): 448-454.

5. McGrogan A, Gemma C, MHelen, Seaman ME. The Epidemiology of Guillain-Barré Syndrome Worldwide. Neuroepidemiology. 2009; 32:150–163.

6. James J, Sejvar ALS, Matthew WB, et al. Population Incidence of Guillain-Barré Syndrome: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2011; 36:123–133.

7. Yuki N, Hartung HP. Guillain–Barré Syndrome. N Engl J Med. 2012; 366:2294-304.

8. Griffin JW1, Li CY, Ho TW, et al. Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases. Brain. 1995 Jun;118 (Pt 3):577-95.

9. Rees JH, Soudain S, etal. Campylobacter jejuni infection and Guillain–Barré syndrome. N Engl J Med. 1995; 333: 1374-9.

10. Ropper AH. The Guillain–Barré Syndrome. N Engl J Med. 1992; 326:1130-1136.

11. Lunn M, Hughes R. The Relationship between Cytomegalovirus Infection and Guillain–Barré Syndrome. Clin Infect Dis. (2011) 52 (7): 845-847.

12. Domínguez-Moreno R, Tolosa-Tort P, et al. Mortalidad asociada al diagnóstico de síndrome de Guillain-Barré en adultos ingresados en instituciones del sistema sanitario mexicano. Rev Neurol. 2014; 58 (1): 4-10.

13. Yu RK, Tsai YT, et al. Structures, biosynthesis, and functions of gangliosides—An overview. J Oleo Sci. 2011; 60(10): 537–544.

14. Yuki N. Guillain–Barré syndrome and anti-ganglioside antibodies: a clinician-scientist’s journey. Proc. Jpn. Acad., Ser 2012; 88: 299-324.

15. Uncini A, Susuki K, Yuki N. Nodo-paranodopathy: Beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies. Clinical Neurophysiology. 124 (2013) 1928–1934.

16. Uncini A, Kuwabara S. Nodopathies of the peripheral nerve: an emerging concept. J Neurol Neurosurg Psychiatry. 2015; 0:1–10.

17. Wim AC, Jacobs BC, Laman JD. The Guillain–Barré syndrome: a true case of molecular mimicry. Trends in Immunology. 2004; 25:1-6.

18. Osler LD, Sidell AD. The Guillain-Barré Syndrome—The Need for Exact Diagnostic Criteria. N Engl J Med. 1960; 262:964-969.

19. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27 Suppl: S21-4.

20. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005; 366: 1653–66.

21. Fokke C, Van den Berg B, et al. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014; (33)137: 33–43.

22. Wakerley BR, Uncini A, Yuki N, et al. Guillain–Barré and Miller Fisher syndromes—new diagnostic classification. Nat. Rev. Neurol. 2014;10: 537–544.

23. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2010;(6):CD002063.

24. Vucic S, Kiernan MC. Guillain-Barre syndrome: An update. Journal of clinical neuroscience. 2009. DOI: 10.1016/j.jocn.2008.08.033

25. Van Koningsveld R, Steyerberg EW, Hughes RA. A clinical prognostic scoring system for Guillain- Barré syndrome. Lancet Neurol. 2007 Jul;6(7):589-94.

26. Walgaard C, Lingsma HF, et al. Early recognition of poor prognosis in Guillain-Barré syndrome. Neurology. 2011 Mar 15; 76(11): 968–975.

27. Howard RS. Poliomyelitis and the postpolio syndrome. BMJ. 2005;330:1314–9

28. García Ramos GS, Cacho Díaz B. Síndrome de Guillain-Barré (SGB). Diagnóstico diferencial. Rev Mex Neuroci. 2005; 6(5): 448-454

29. Yuki N. Relation between critical illness polyneuropathy and axonal Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 1999; 67:121–133

30. Wöhrle JC, MD; Spengos K. Alcohol-Related Acute Axonal Polyneuropathy: A Differential Diagnosis of Guillain-Barré Syndrome. Arch Neurol. 1998;55(10):1329-1334.

31. Martens-Le Bouar H, Korinthenberg R. Polyradiculoneuritis with myelitis: a rare differential diagnosis of Guillain-Barre syndrome. Neuropediatrics. 2002, 33(2):93-96.

32. Hughes RA, Wijdicks FM, et al. Supportive Care for Patients with Guillain-Barré Syndrome. Arch Neurol. 2005;62(8):1194-1198.

33. Ruts L, Drenthen J, Jacobs BC, van Doorn PA, Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology. 2010;74(21):1680.

34. Hughes RA, Wijdicks FM, et al. Practice parameter: Immunotherapy for Guillain–Barré syndrome. Neurology. 2003; 61:736–740.

35. Willison HJ, Jacobs BC, Doorn PA. Guillain-Barré syndrome. Lancet Seminar. 2016: http://dx.doi. org/10.1016/S0140-6736(16)00339-1.

36. Goodfellow JA and Willison HJ. Guillain–Barré syndrome: a century of progress. Nat Rev Neurol. 2016 Dec;12(12):723-731.